JPRN-UMIN000001060已完成2 期
Phase II Study of FOLFIRI Plus Bevacizumab (AVASIRI) in Patients as Second Line Chemotherapy of Unresectable Colorectal Cancer - AVASIRI trial
ational Cancer Center Hospital, Gastrointestinal Oncology Division0 个研究点目标入组 35 人开始时间: 2008年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active double cancer 2) Serious drug hypersensitivity or a history of drug allergy 3) Active infections 4) Serious complications (e.g., intestinal tract paralysis, ileus, pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure or hepatic failure.) 5) Uncontrolled hypertension 6) Abnormal EKG 7) Severe ascites 8) Metastasis to the CNS 9) History or evidence of inherited bleeding diathesis 10) Coagulopathy with the risk of bleeding 11) Patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism 12) HBs Ab positive, HCV At positive 13) Uncontrolled watery diarrhea 14) Major surgical procedure within 4 weeks 15) Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children. 16) Judged ineligible for participation in the study by the investigator for safety reasons.
研究者
相似试验
已完成
2 期
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.Recurrent or metastatic colorectal cancerJPRN-UMIN000004219Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology40
已完成
2 期
Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.Colorectal cancerJPRN-UMIN000001437Japan Clinical Cancer Research Organization40
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
招募中
2 期
A phase II trial of FOLFOXIRI+Bevacizumab as preoperative chemotherapy for locally advanced lower rectal cancerower rectal cancerJPRN-UMIN000031028Kobe University Graduate School of Medicine40
已完成
不适用
Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)BRAF V600E-mutant Metastatic Colorectal CancerJPRN-UMIN000041098West Japan Oncology Group250